Showing 301-310 of 1560 results for "".
Investigator Perspectives on Treating Patients in a Ph2 NSCLC Trial
https://reachmd.com/programs/project-oncology/investigator-perspectives-on-treating-patients-in-a-ph2-nsclc-trial/26564/High c-MET protein overexpression is a MET aberration2,3 seen in about 1 in 7 or 14% of patients with EGFR wild-type non-squamous non-small cell lung cancer (NSCLC) tumors. Telisotuzumab vedotin-tllv (Teliso-V) is a first-in-class, c-Met protein-directed antibody-drug conjugate that was studied in tTracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
https://reachmd.com/programs/project-oncology/lineage-infidelity-pediatric-b-all-ash/39976/New data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition reveals how chemotherapy and immunotherapy may drive the emergence of CD-19–negative, myeloid-like subclones in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Mr. Ryan Quigley sits down with Dr. KathThe Alloimmune Disorders of Pregnancy: Optimizing Fetal Outcomes Through Advances in Diagnosis and Treatment
https://reachmd.com/programs/cme/the-alloimmune-disorders-of-pregnancy-optimizing-fetal-outcomes-through-advances-in-diagnosis-and-treatment/32929/How does the pathophysiology of HDFN and FNAIT offer clues to improving diagnosis and treatment outcomes? Drs. Goodnight and Markham have answers.Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
https://reachmd.com/programs/project-oncology/investigating-at-home-subcutaneous-atezolizumab-for-nsclc-an-ongoing-study/35769/Can the immune checkpoint inhibitor atezolizumab be safely administered subcutaneously at home for patients with non-small cell lung cancer (NSCLC)? That’s the exact question an ongoing study is seeking to answer, and here to discuss the study’s objective, design, and potential implications for homeA Life on the Front Lines: The Journey of an Abortion Doctor
https://reachmd.com/programs/clinicians-roundtable/a-life-on-the-front-lines-the-journey-of-an-abortion-doctor/2985/Enduring death threats and other abuse, carrying a concealed weapon, and wearing a bulletproof vest were as much a part of a normal day for Dr. Susan Wicklund as sipping a cup of coffee or talking on a cell phone. Dr. Michael Greenberg hosts this can’t-miss discussion, no matter your views, explorinMedical Myths Even Docs Believe
https://reachmd.com/programs/clinicians-roundtable/medical-myths-even-docs-believe/2733/Turkey gets a bad rap for its tryptophan levels. Ditto cell phones for disrupting sensitive life support instruments. And what about this notion that we only use 10% of our brains? Dr. Aaron Carroll, assistant professor of pediatrics at Indiana University School of Medicine, and author of the articlCost Considerations for Colorectal Cancer Screening: Examining the Data
https://reachmd.com/programs/clinicians-roundtable/cost-considerations-for-colorectal-cancer-screening-examining-the-data/33054/A recent study explored three emerging colorectal cancer (CRC) screening tests—mt-sRNA, multitarget stool DNA 2.0, and cell-free DNA—in terms of their cost-effectiveness, comparing them to traditional methods such as colonoscopy and fecal immunochemical testing. Learn which methods offer the best ba6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
https://reachmd.com/programs/project-oncology/6-year-outcomes-from-checkmate-9la-efficacy-and-safety-across-nsclc-subgroups/35999/The CheckMate 9LA study examined the long-term efficacy and safety of nivolumab plus ipilimumab and chemotherapy in various metastatic non-small cell lung cancer subtypes, including patients with low PD-L1 expression, squamous histology, and KRAS or STK11 mutations. Joining Dr. Jacob Sands to discusOptimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
https://reachmd.com/programs/Audioabstracts/monitoring-ide-cel-rrmm/48730/As CAR T-cell therapy becomes more widely used in multiple myeloma, understanding when toxicities occur is critical to balancing safety and access. Hear from Dr. Mimi Maeusli as she reviews new clinical and real-world findings on post-infusion monitoring for idecabtagene vicleucel (ide-cel) in patieMonitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
https://reachmd.com/programs/project-oncology/monitoring-adverse-events-post-car-t-the-latest-approaches-and-best-practices/36484/As CAR T-cell therapy advances, so does the complexity of adverse event monitoring. Due to evolving insights into acute toxicities, infections, cytopenias, and secondary malignancies, both inpatient and outpatient care models are adapting to meet new standards. Joining Dr. Charles Turck to discuss p